-
Je něco špatně v tomto záznamu ?
Induction of fecal cholesterol excretion is not effective for the treatment of hyperbilirubinemia in Gunn rats
M. Blankestijn, IP. van de Peppel, A. Dvorak, N. Capkova, L. Vitek, JW. Jonker, HJ. Verkade
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Free Medical Journals
od 1967 do Před 1 rokem
ProQuest Central
od 2016-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2016-01-01 do Před 1 rokem
Public Health Database (ProQuest)
od 2021-01-01 do 2021-12-31
- MeSH
- bilirubin chemie MeSH
- cholesterol metabolismus MeSH
- Criglerův-Najjarův syndrom metabolismus terapie MeSH
- dietní tuky farmakokinetika MeSH
- ezetimib farmakologie terapeutické užití MeSH
- feces chemie MeSH
- fluorované uhlovodíky farmakologie terapeutické užití MeSH
- haptoglobiny analýza MeSH
- hyperbilirubinemie terapie MeSH
- jaterní receptor X metabolismus MeSH
- krysa rodu rattus MeSH
- kyselina chenodeoxycholová analogy a deriváty farmakologie terapeutické užití MeSH
- lipidy krev MeSH
- náhodné rozdělení MeSH
- potkani Gunn MeSH
- PPAR delta metabolismus MeSH
- receptory cytoplazmatické a nukleární metabolismus MeSH
- střeva účinky léků metabolismus MeSH
- sulfonamidy farmakologie terapeutické užití MeSH
- žluč chemie MeSH
- žlučové kyseliny a soli metabolismus MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: Unconjugated hyperbilirubinemia, a feature of neonatal jaundice or Crigler-Najjar syndrome, can lead to neurotoxicity and even death. We previously demonstrated that unconjugated bilirubin (UCB) can be eliminated via transintestinal excretion in Gunn rats, a model of unconjugated hyperbilirubinemia, and that this is stimulated by enhancing fecal fatty acid excretion. Since transintestinal excretion also occurs for cholesterol (TICE), we hypothesized that increasing fecal cholesterol excretion and/or TICE could also enhance fecal UCB disposal and subsequently lower plasma UCB concentrations. METHODS: To determine whether increasing fecal cholesterol excretion could ameliorate unconjugated hyperbilirubinemia, we treated hyperbilirubinemic Gunn rats with ezetimibe (EZE), an intestinal cholesterol absorption inhibitor, and/or a liver X receptor (LXR) and farnesoid X receptor (FXR) agonist (T0901317 (T09) and obeticholic acid (OCA), respectively), known to stimulate TICE. RESULTS: We found that EZE treatment alone or in combination with T09 or OCA increased fecal cholesterol disposal but did not lower plasma UCB levels. CONCLUSIONS: These findings do not support a link between the regulation of transintestinal excretion of cholesterol and bilirubin. Furthermore, induction of fecal cholesterol excretion is not a potential therapy for unconjugated hyperbilirubinemia. IMPACT: Increasing fecal cholesterol excretion is not effective to treat unconjugated hyperbilirubinemia. This is the first time a potential relation between transintestinal excretion of cholesterol and unconjugated bilirubin is investigated. Transintestinal excretion of cholesterol and unconjugated bilirubin do not seem to be quantitatively linked. Unlike intestinal fatty acids, cholesterol cannot "capture" unconjugated bilirubin to increase its excretion. These results add to our understanding of ways to improve and factors regulating unconjugated bilirubin disposal in hyperbilirubinemic conditions.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22012534
- 003
- CZ-PrNML
- 005
- 20220506130146.0
- 007
- ta
- 008
- 220425s2021 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41390-020-0926-2 $2 doi
- 035 __
- $a (PubMed)32357361
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Blankestijn, Maaike $u Section of Molecular Metabolism and Nutrition, Department of Pediatrics, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands
- 245 10
- $a Induction of fecal cholesterol excretion is not effective for the treatment of hyperbilirubinemia in Gunn rats / $c M. Blankestijn, IP. van de Peppel, A. Dvorak, N. Capkova, L. Vitek, JW. Jonker, HJ. Verkade
- 520 9_
- $a BACKGROUND: Unconjugated hyperbilirubinemia, a feature of neonatal jaundice or Crigler-Najjar syndrome, can lead to neurotoxicity and even death. We previously demonstrated that unconjugated bilirubin (UCB) can be eliminated via transintestinal excretion in Gunn rats, a model of unconjugated hyperbilirubinemia, and that this is stimulated by enhancing fecal fatty acid excretion. Since transintestinal excretion also occurs for cholesterol (TICE), we hypothesized that increasing fecal cholesterol excretion and/or TICE could also enhance fecal UCB disposal and subsequently lower plasma UCB concentrations. METHODS: To determine whether increasing fecal cholesterol excretion could ameliorate unconjugated hyperbilirubinemia, we treated hyperbilirubinemic Gunn rats with ezetimibe (EZE), an intestinal cholesterol absorption inhibitor, and/or a liver X receptor (LXR) and farnesoid X receptor (FXR) agonist (T0901317 (T09) and obeticholic acid (OCA), respectively), known to stimulate TICE. RESULTS: We found that EZE treatment alone or in combination with T09 or OCA increased fecal cholesterol disposal but did not lower plasma UCB levels. CONCLUSIONS: These findings do not support a link between the regulation of transintestinal excretion of cholesterol and bilirubin. Furthermore, induction of fecal cholesterol excretion is not a potential therapy for unconjugated hyperbilirubinemia. IMPACT: Increasing fecal cholesterol excretion is not effective to treat unconjugated hyperbilirubinemia. This is the first time a potential relation between transintestinal excretion of cholesterol and unconjugated bilirubin is investigated. Transintestinal excretion of cholesterol and unconjugated bilirubin do not seem to be quantitatively linked. Unlike intestinal fatty acids, cholesterol cannot "capture" unconjugated bilirubin to increase its excretion. These results add to our understanding of ways to improve and factors regulating unconjugated bilirubin disposal in hyperbilirubinemic conditions.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a žluč $x chemie $7 D001646
- 650 _2
- $a žlučové kyseliny a soli $x metabolismus $7 D001647
- 650 _2
- $a bilirubin $x chemie $7 D001663
- 650 _2
- $a kyselina chenodeoxycholová $x analogy a deriváty $x farmakologie $x terapeutické užití $7 D002635
- 650 _2
- $a cholesterol $x metabolismus $7 D002784
- 650 _2
- $a Criglerův-Najjarův syndrom $x metabolismus $x terapie $7 D003414
- 650 _2
- $a dietní tuky $x farmakokinetika $7 D004041
- 650 _2
- $a ezetimib $x farmakologie $x terapeutické užití $7 D000069438
- 650 _2
- $a feces $x chemie $7 D005243
- 650 _2
- $a haptoglobiny $x analýza $7 D006242
- 650 _2
- $a fluorované uhlovodíky $x farmakologie $x terapeutické užití $7 D006845
- 650 _2
- $a hyperbilirubinemie $x terapie $7 D006932
- 650 _2
- $a střeva $x účinky léků $x metabolismus $7 D007422
- 650 _2
- $a lipidy $x krev $7 D008055
- 650 _2
- $a jaterní receptor X $x metabolismus $7 D000071518
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a PPAR delta $x metabolismus $7 D047494
- 650 _2
- $a náhodné rozdělení $7 D011897
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Gunn $7 D011911
- 650 _2
- $a receptory cytoplazmatické a nukleární $x metabolismus $7 D018160
- 650 _2
- $a sulfonamidy $x farmakologie $x terapeutické užití $7 D013449
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a van de Peppel, Ivo P $u Section of Molecular Metabolism and Nutrition, Department of Pediatrics, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands
- 700 1_
- $a Dvorak, Ales $u Institute of Medical Biochemistry and Laboratory Diagnostics, Faculty General Hospital and First Faculty of Medicine, Charles University, Na Bojisti 3, 12108, Prague, Czech Republic
- 700 1_
- $a Capkova, Nikola $u Institute of Medical Biochemistry and Laboratory Diagnostics, Faculty General Hospital and First Faculty of Medicine, Charles University, Na Bojisti 3, 12108, Prague, Czech Republic
- 700 1_
- $a Vitek, Libor $u Institute of Medical Biochemistry and Laboratory Diagnostics, Faculty General Hospital and First Faculty of Medicine, Charles University, Na Bojisti 3, 12108, Prague, Czech Republic
- 700 1_
- $a Jonker, Johan W $u Section of Molecular Metabolism and Nutrition, Department of Pediatrics, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands
- 700 1_
- $a Verkade, Henkjan J $u Section of Molecular Metabolism and Nutrition, Department of Pediatrics, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands. h.j.verkade@umcg.nl
- 773 0_
- $w MED00003741 $t Pediatric research $x 1530-0447 $g Roč. 89, č. 3 (2021), s. 510-517
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32357361 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130138 $b ABA008
- 999 __
- $a ok $b bmc $g 1789933 $s 1163735
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 89 $c 3 $d 510-517 $e 20200501 $i 1530-0447 $m Pediatric research $n Pediatr Res $x MED00003741
- LZP __
- $a Pubmed-20220425
